Stock listing

TASE:KMDA Kamada Ltd. מניה‎

Israeli listing (TASE) of Kamada Ltd. · home listing NASDAQ:KMDA

Follow Kamada Ltd. into a list and get an email when it puts out news.

Share price · TASE:KMDA

2,421.00 ILA (agorot) -1.00 (-0.0%)

Close on Oct 22, 2026

Day range
2,390.00 – 2,434.00 ILA (agorot)Oct 22, 2026
Volume
22,152 sharesOct 22, 2026
Kamada Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KMDA · Home$7.70 USD-0.25 (-3.1%)47,253$7.88$7.88$7.67$7.95Close on Oct 30, 2026
TASE:KMDA2,421.00 ILA (agorot)-1.00 (0.0%)22,1522,422.002,434.002,390.002,422.00Close on Oct 22, 2026
Ticker
TASE:KMDA
Asset type
Stock
Exchange
TASE
Currency
ILA

What changed lately

Calls

Replays

  • Kamada (NASDAQ:KMDA) Q2 2026 Earnings Call

    Wed, Aug 12, 2026 · 8:30 AM ET

    Watch Transcript

  • Kamada (NASDAQ:KMDA) Q1 2026 Earnings Call

    Wed, May 13, 2026 · 8:30 AM ET

    Watch Transcript

  • Kamada (NASDAQ:KMDA) Q4 2025 Earnings Call

    Wed, Mar 11, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

Oct 19, 2026

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Oct 6, 2026

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

Sep 17, 2026

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Aug 12, 2026

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Aug 5, 2026

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Jul 20, 2026

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

Jul 13, 2026

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory

Jun 1, 2026

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

May 13, 2026

All Kamada Ltd. news

Decks

Kamada Ltd. on 6ix

News releases
24 in the last 12 months · 119 in all · newest Oct 19, 2026 · oldest 2020
Calls
23 calls with a replay · 23 with a transcript · latest Aug 12, 2026
Decks
30 decks · latest Aug 12, 2026

Where Kamada Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:KMDA · Home listingNASDAQUnited StatesUSD
TASE:KMDA · This pageTASEIsraelILA
BOATS:KMDABOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Kamada Ltd.